AI in cell and gene therapy – a glimpse into the future while facing reality
Cell and Gene Therapy Insights · 07.08.2026 · 12 (6) · 691–695
DOI: 10.18609/cgti.2026.083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell and Gene Therapy Insights, online erschienen am 07.08.2026. Verfasst von Nina Bauer. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
“By identifying common rules across data sets and modalities, AI could help the field move from bespoke, heterogeneous products toward a more synthetic biology oriented approach.”Cell and gene therapies (CGT) have gained medical acceptance because of their curative potential, yet patient access remains constrained by cost of goods, manufacturing and supply chain complexity, proximity to suitable hospitals, and development cycles complicated by patient to patient variability. Increasingly, AI is being positioned not as a peripheral addon, but as a foundational enabler for the field. It is my privilege to introduce this month’s edition of CGT Insights with an inaugural AI focus, where the authors explore how machine learning (ML) and AI can improve multiple stages of the therapeutic lifecycle.
Zitieren
APA
Bauer, N. (2026). AI in cell and gene therapy – a glimpse into the future while facing reality. Cell and Gene Therapy Insights, 12(6), 691–695. https://doi.org/10.18609/cgti.2026.083
Vancouver
Bauer N. AI in cell and gene therapy – a glimpse into the future while facing reality. Cell and Gene Therapy Insights. 2026;12(6):691–695. doi:10.18609/cgti.2026.083
BibTeX
@article{Bauer2026,
author = {Bauer, Nina},
title = {AI in cell and gene therapy – a glimpse into the future while facing reality},
journal = {Cell and Gene Therapy Insights},
year = {2026},
volume = {12},
number = {6},
pages = {691–695},
doi = {10.18609/cgti.2026.083}
}
EUVIMED